PI6.F
Healthcare BiotechnologyPalvella Therapeutics, Inc.
€118.00
+1.00 +0.85% today
Price History
Not enough data
Key Stats
Market Cap
1.69B
Avg Volume
7
EPS
-€4.16
52W High
€137.00
52W Low
€55.50
Div. Yield
0.0%
Valuation
P/B Ratio
9.09
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(46.6%)
Return on Assets
(22.1%)
Liquidity & Leverage
Current Ratio
21.18
Quick Ratio
21.01
Debt / Equity
0.10
Total Cash
250.58M
Total Debt
22.64M
About
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
palvellatx.com